Skip to main content
WeightCited

CLA pour Obesity

B

Cochrane meta-analysis of 18 RCTs (n=807) found CLA at 3.2 g/day reduced body fat mass by 1.33 kg over 6-12 months without significant change in body weight, suggesting lean mass preservation. A 2-year RCT (n=134) found sustained fat reduction. Effects are modest and require long-term use.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'weightcited.com'; const params = 'ingredient\u003Dcla\u0026condition\u003Dobesity'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

B

En conclusion

Cochrane meta-analysis of 18 RCTs (n=807) found CLA at 3.2 g/day reduced body fat mass by 1.33 kg over 6-12 months without significant change in body weight, suggesting lean mass preservation. A 2-year RCT (n=134) found sustained fat reduction. Effects are modest and require long-term use.

Key Statistics

18

Études

807

Participants

Positive

B

Note

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Posologies couramment utilisées

general:
3.2-6.4 g/day mixed isomers
bodycomposition:
3.4 g/day (50:50 c9,t11:t10,c12 blend)
minimumeffective:
3.2 g/day for ≥12 weeks

Limite supérieure : 6 g/day; higher doses may worsen insulin sensitivity

Moment optimal de prise : With meals; divide dose across 2-3 meals

Safety & Side Effects

Effets indésirables signalés

  • GI discomfort
  • May worsen insulin sensitivity at high doses
  • Possible HDL reduction
  • Fatty liver (in some rodent studies)

Interactions connues

  • Diabetes medications (may affect insulin sensitivity)
  • Blood thinners (theoretical)

Apport maximal tolérable : 6 g/day; higher doses may worsen insulin sensitivity

Consultez toujours votre professionnel de santé avant de commencer tout complément alimentaire.Consultez toujours votre professionnel de santé avant de commencer tout complément alimentaire.

Frequently Asked Questions

Does CLA help with Obesity?
Based on 18 studies with 807 participants, there is moderate evidence from clinical studies that CLA may support Obesity management. Our evidence grade is B (Good Evidence).
How much CLA should I take for Obesity?
Studies have used various dosages. A commonly studied range is 3.2-6.4 g/day mixed isomers. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of CLA?
Reported side effects may include GI discomfort, May worsen insulin sensitivity at high doses, Possible HDL reduction, Fatty liver (in some rodent studies). Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for CLA and Obesity?
We rate the evidence as Grade B (Good Evidence). This rating is based on 18 peer-reviewed studies with 807 total participants. The overall direction of effect is positive.

Related Evidence

Avertissement FDA: Ces déclarations n'ont pas été évaluées par la Food and Drug Administration. Les produits et informations sur ce site ne sont pas destinés à diagnostiquer, traiter, guérir ou prévenir quelque maladie que ce soit. Les notes de preuve présentées sont basées sur notre analyse de la recherche publiée et évaluée par des pairs et ne constituent pas un avis médical. Consultez toujours votre professionnel de santé avant de commencer tout régime de compléments alimentaires.